Previous phase I/II studies on first‐line or second‐line therapy with osimertinib and bevacizumab did not show prolonged PFS in NSCLC patients with EGFR or EGFR T790M mutations.12, 14. This evidence concerns the gene EGFR and non-small cell lung carcinoma.